Omeros Announces Webcast Details for Annual Meeting of Shareholders
June 15 2022 - 8:00AM
Business Wire
Omeros Corporation (Nasdaq: OMER), today announced that the
company will host a live webcast of its Annual Meeting of
Shareholders, which will be held virtually, on Friday, June 17,
2022, starting at 10:00 a.m. Pacific Time.
The live webcast of the Annual Meeting of Shareholders can be
accessed through www.virtualshareholdermeeting.com/OMER2022. A
general corporate overview and question and answer session is
expected to follow the business portion of the annual meeting.
As described in the Company’s proxy statement, filed May 2,
2022, only shareholders of record as of the close of business on
April 14, 2022, are entitled to vote at the Annual Meeting of
Shareholders and any adjournment or postponement thereof.
Shareholders of record will be able to attend the meeting, vote and
submit questions via the Internet at
www.virtualshareholdermeeting.com/OMER2022 using the 16-digit
control number provided in their proxy card or in the instructions
accompanying their proxy materials.
Guests without a 16-digit control number may also attend the
Annual Meeting by accessing the website listed above, but will not
have the option to vote or ask questions.
For those unable to attend the live event, a recording will be
archived and accessible at
https://investor.omeros.com/archived-events.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to
discovering, developing and commercializing small-molecule and
protein therapeutics for large-market and orphan indications
targeting immunologic diseases, including complement-mediated
diseases and cancers related to dysfunction of the immune system,
as well as addictive and compulsive disorders. Omeros’ lead MASP-2
inhibitor narsoplimab targets the lectin pathway of complement and
is the subject of a biologics license application pending before
FDA for the treatment of hematopoietic stem cell
transplant-associated thrombotic microangiopathy. Narsoplimab is
also in multiple late-stage clinical development programs focused
on other complement-mediated disorders, including IgA nephropathy,
atypical hemolytic uremic syndrome and COVID-19. OMS906, Omeros’
inhibitor of MASP-3, the key activator of the alternative pathway
of complement, is initiating a Phase 1b clinical program in
paroxysmal nocturnal hemoglobinuria (PNH). In addition to its
complement franchise, Omeros has ongoing cutting-edge programs in
addiction treatments, immuno-oncology therapeutics and human CAR-T
and adoptive T cell therapy systems. More information about Omeros
and its programs is available at www.omeros.com and in Omeros’
annual, quarterly and current reports filed with the U.S.
Securities and Exchange Commission (SEC), which can be accessed at
www.omeros.com under “Investors & News — Financial Information
— SEC Filings” and on the SEC’s website at www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220615005479/en/
Jennifer Cook Williams Cook Williams Communications, Inc.
Investor and Media Relations 360.668.3701 jennifer@cwcomm.org
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Aug 2024 to Sep 2024
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Sep 2023 to Sep 2024